Abstract
Afatinib has shown encouraging results in EGFR mutation (+) patients. According to LUX-Lung trials, afatinib is known to be effective in delaying the occurrence of brain metastases, and it is also known to be effective in treating patients with brain metastases by penetrating the blood-brain barrier. We conducted a study on the effect on brain metastasis in EGFR M(+) patients who received afatinib as the 1st line from the KATRD EGFR cohort data.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
